Das diffuse maligne peritoneale Mesotheliom (DMPM) – eine seltene Diagnose

Habbel, Victoria Susanne Antonia; Mahler, E.; Feyerabend, Bernd; Oldhafer, K.; Lipp, Michael

doi:10.1055/a-1083-6962

Cited by 3 publications

(4 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The following may be helpful for the diagnosis: high levels of platelets, IL-6 and CA-125; massive ascites with high levels of IL-6 or CA-125; peritoneal thickening and abdominal lymph nodes showed by MRI; histopathological and immunohistochemical examination results. In the peripheral blood of DMPM patients, CA-125 increased in 53% of patients, [8] while 83% of them had increased platelets. Meanwhile, the ascites puncture is often negative, as only a few malignant cells presenting in ascites, and the diagnosis can only be made from tissue samples ultimately.…”

Section: Discussionmentioning

confidence: 99%

Metachronous double primary malignant tumors with nasopharyngeal carcinoma and diffuse malignant peritoneal mesothelioma accompanied with paraneoplastic syndromes treated with nivolumab: A case report

Tang

Xiang

et al. 2023

Medicine

View full text Add to dashboard Cite

Rationale: Multiple primary malignant tumors are rare and challenging to diagnose. Diffuse malignant peritoneal mesothelioma (DMPM) originate from the peritoneum, which lacks specific clinical manifestations and is difficult to diagnose, with a short survival about 10 to 13 months for inoperable ones. This is the first report of metachronous double primary malignant tumors in nasopharyngeal carcinoma and DMPM accompanied with paraneoplastic syndromes. Patient concerns: A 61-year-old man presented with abdominal discomfort with a history of nasopharyngeal carcinoma 5 years ago. Diagnoses: The diagnosis of DMPM was finally confirmed by laparoscopic mesenteric biopsies. Paraneoplastic syndromes including increased platelets were present when diagnosis, followed by increased neutrophils after disease progression. Interventions: Due to intolerable for surgery, he was treated with pemetrexed combined with nivolumab, intraperitoneal infusion of nivolumab, radiotherapy, anlotinib and maintenance treatment of nivolumab. Outcomes: Progression-free survival in first line is 12 months, overall survival is 23 months. Lessons: This indicate that comprehensive treatment including immunotherapy may be helpful for inoperable DMPM patients with nasopharyngeal carcinoma accompanied with paraneoplastic syndromes.

show abstract

Section: Discussionmentioning

confidence: 99%

Metachronous double primary malignant tumors with nasopharyngeal carcinoma and diffuse malignant peritoneal mesothelioma accompanied with paraneoplastic syndromes treated with nivolumab: A case report

Tang

Xiang

et al. 2023

Medicine

View full text Add to dashboard Cite

show abstract

“…New chemotherapeutic agents such as anti-mesothelin antibody (anetumumab), anti-PDL-1 (pembrolizumab), CAR T cells, and Listeria-based immunotherapy can improve the survival of patients with PMP. There are still no clear recommendations in the follow-up of patients with MPM after radical excision surgery [40]. There is a follow-up guide developed by the European Society for Medical Oncology for pleural mesothelioma, but no frequency or methods of investigation used in the postoperative period (CT, MRI, or ultrasonography) are specified.…”

Section: Recommendations In the Treatment Of Mpmmentioning

confidence: 99%

Peritoneal Mesothelioma: Clinical and Therapeutic Aspects

Meşină¹,

Mesina-Botoran²,

Dumitrescu³

et al. 2020

Mesothelioma

View full text Add to dashboard Cite

Mesothelioma is a very rare malignant disease that originates from mesothelial cells that line the serosa: pleura, peritoneum, pericardium, or testicular vaginal tunic. Peritoneal mesothelioma accounts for 7–10% of all mesotheliomas diagnosed, and ranks second after pleural localization of mesothelioma. The incidence of peritoneal mesothelioma is 0.5–3 cases per million in men and 0.2–2 cases per million in women. Diagnosis of peritoneal mesothelioma is difficult due to nonspecific symptoms and because of this patients present in advanced stages of the disease. Histologically there are three major categories of malignant peritoneal mesothelioma: epithelioid, sarcomatoid, and biphasic. The differential diagnosis of peritoneal mesothelioma is made with peritoneal pseudomyxoma, ovarian tumors, and peritoneal metastases from colorectal cancer. An important role in differential diagnosis, in addition to immunohistochemistry, is played by various tumor markers and genetic tests. The treatment of peritoneal mesothelioma is performed by cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), with good results for patients in the early stages of the disease. For patients with advanced disease, a new treatment has been proposed: pressurized intraperitoneal aerosol chemotherapy (PIPAC). For patients who cannot use CRS and HIPEC, the only therapeutic option remains chemotherapy (systemic + intraperitoneal).

show abstract

“…Diffuse malignant peritoneal mesothelioma (DMPM) is a rare malignancy characterized by highly malignant behavior and poor prognosis (1). The median overall survival (OS) of the patients was about 4-13 months treated by traditional treatment strategies, such as palliative surgery, intravenous and intraperitoneal chemotherapy (2,3).…”

Section: Introductionmentioning

confidence: 99%

“…The median overall survival (OS) of the patients was about 4-13 months treated by traditional treatment strategies, such as palliative surgery, intravenous and intraperitoneal chemotherapy (2,3). The implementation of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) dramatically prolonged the OS of DMPM to 30-92 months, and a meta-analysis of 20 publications with data on outcomes of 1047 patients with DMPM treated with CRS and HIPEC reported a 5-year survival of 42% (1,(4)(5)(6). However, postoperative recurrence is still an important cause of death for most patients, and some still showed no benefits from CRS and HIPEC (7).…”

Section: Introductionmentioning

confidence: 99%

Efficacy and Adverse Events of Apatinib Salvage Treatment for Refractory Diffuse Malignant Peritoneal Mesothelioma: A Pilot Study

Yang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveTo investigate the clinical efficacy and adverse events (AEs) of apatinib salvage treatment for diffuse malignant peritoneal mesothelioma (DMPM) that has failed to respond to the recommended treatments.Methods27 patients with refractory DMPM were treated with apatinib at our center from April 2014 to October 2020, at the initial dose of 250 mg/d. The dose was reduced to 125 mg/d when serious adverse events (SAEs) occurred. 28-day was set as a treatment cycle. The frequency of follow up was once every 28 days. The efficacy evaluation was conducted according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria and the serum tumor markers before and after apatinib treatment. The safety assessment was performed with the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The primary endpoints were objective response rate (ORR) and disease control rate (DCR), and the secondary endpoints were AEs.ResultsThe 27 patients completed a median treatment-cycle of 15.0, ranging from 5.1 to 39.4 cycles. At the median follow-up of 14.3 (4.8-51.8) months, median overall survival (OS) was 59.4 months, median apatinib-treatment-related survival (ATRS) was 14.0 (4.8-36.8) months. Complete response (CR) was observed in 0 case (0.0%), partial response (PR) in 4 cases (14.8%), stable disease (SD) in 12 cases (44.4%), and progression disease (PD) in 11 cases (40.7%). The ORR was 14.8%, and DCR was 59.3%. The median serum CA125 values before and after apatinib treatment were 32.9 (7.0-4592.4) U/mL and 29.7 (6.1-4327.4) U/mL, respectively (P=0.009). The common AEs were hypertension (6/27; 22.2%), hand-foot syndrome (5/27; 18.5%), albuminuria (4/27; 14.8%), anemia (4/27; 14.8%), leukopenia (4/27; 14.8%), rash (2/27; 7.4%), fatigue (2/27; 7.4%), oral ulcers (2/27; 7.4%), hoarseness (2/27; 7.4%), nausea/vomiting (2/27; 7.4%), diarrhea (2/27; 7.4%), headache (1/27; 3.7%), and fever (1/27; 3.7%). The incidence rate of grade III/IV AEs was 16.2%.ConclusionsApatinib is effective in treating refractory DMPM, with promising efficacy and acceptable safety.

show abstract

Das diffuse maligne peritoneale Mesotheliom (DMPM) – eine seltene Diagnose

Cited by 3 publications

References 36 publications

Metachronous double primary malignant tumors with nasopharyngeal carcinoma and diffuse malignant peritoneal mesothelioma accompanied with paraneoplastic syndromes treated with nivolumab: A case report

Metachronous double primary malignant tumors with nasopharyngeal carcinoma and diffuse malignant peritoneal mesothelioma accompanied with paraneoplastic syndromes treated with nivolumab: A case report

Peritoneal Mesothelioma: Clinical and Therapeutic Aspects

Efficacy and Adverse Events of Apatinib Salvage Treatment for Refractory Diffuse Malignant Peritoneal Mesothelioma: A Pilot Study

Contact Info

Product

Resources

About